Technical Data
D9099-45
Doxorubicin (DXR, 14-Hydroxydaunomycin, Adriamycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, Farmiblastina, FI 106, K 1039, KW 125, NSC 123127)
Description:
Doxorubicin is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumor agent for the treatment of a wide range of cancers. Doxorubicin has also been reported to exhibit anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

Applications:
Suitable for use in ELISA and Functional Applications. Other applications have not been tested.

Recommended Dilutions:
Functional Applications: In vivo antidotic effect
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG26D359 (MAD11)Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceMouse
Concentration:
~1mg/ml
Immunogen:
Doxorubicin, conjugated to BSA.
Purity:
Purified
Form
Supplied as a liquid in 150mM sodium chloride, pH 7.4, 0.02% sodium azide.
Specificity:
Recognizes anthracycline compounds including doxorubicin analogs and derivatives.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Monoclonal antibodies against doxorubicin: A. Balsari, et al.; Int. J. Cancer 42, 798 (1988) Abstracte: A. Balsari, et al.; Anticancer Res. 10, 129 (1990) 2. A. Balsari, et al.; Int. J. Cancer 47, 889 (1991) 3. A. Sardini, et al.; Int. J. Cancer 50, 617 (1992) 4. : A.L. Balsari, et al.; FASEB J. 8, 226 (1994) 5.: D. Morelli, et al.; Cell Biophys. 24-25, 119 (1994) 6. i, et al.; Scand. J. Immunol. 39, 453 (1994) 7. D. Morelli, et al.; Cancer Res. 56, 2082 (1996) 8. R. Cece, et al.; Lab. Invest. 75, 601 (1996) 9. Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice: D. Morelli, et al.; Br. J. Cancer 75, 656 (1997) 10. A. Balsari, et al.; Br. J. Cancer 85, 1964 (2001) 11. M. Campiglio, et al.; Int. J. Cancer 105, 568 (2003)